Orsenix Holdings BV
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Orsenix Holdings BV
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
Syros has failed to progress in its leukemia niche since its launch a few years ago, but a new drug candidate and funding could revive its fortunes.